What is RARE's market cap?

$1.47B, based on the Oct 14 close of $14.90.

Does Ultragenyx Pharmaceutical pay a dividend?

No regular cash dividend has been paid in the last year.

How much of RARE is sold short?

20.3M shares, 21.8% of float, as of Sep 30, 2026.

What sector is RARE in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · RAREHealthcarePharmaceuticals

Ultragenyx Pharmaceutical Inc. (RARE)

$14.90−0.13%

Close Oct 14, 2026 · split-adjusted

Oct 14, 2026$14.90▼ 52.98% in range

Oct 14, 2025Low $12.88 · High $36.54Oct 14, 2026

What changed · written from our data

As of Oct 14, 2026

Ultragenyx Pharmaceutical closed at $14.90 on Oct 14, down 0.13%, 59.2% below its 52-week closing high. Volume of 3.0M shares was 0.54× its 20-day average (below normal).

Split-adjusted performance: +14.0% over one month, -40.8% over six months, -53.5% over one year.

In the quarter ended Jun 30, 2026, revenue was $214M, up 28.1% from a year earlier, with a net margin of -43.0%.

Short interest was 20.3M shares at the Sep 30 settlement, up 22.8% from the prior report (21.8% of float, 3.1 days to cover).

Market cap$1.47B98.6M shares

Revenue · quarter$214.0M+28.1% YoY

Diluted EPS$-0.90—

P/E · TTM—P/S 2.0×

Net margin-43.0%Gross 84.1%

Dividend yieldNone

52-week range12.88 – 36.54−59.2% from high

Volume3.0M0.54× 20-day avg

Volatility · 60d127.6%Annualised

Short % of float21.8%3.1 days to cover

Net cash$292.0MCash $292.0M

Next earnings—Not scheduled

Split-adjusted performance

1W +0.1%1M +14.0%3M −50.7%6M −40.8%YTD −35.2%1Y −53.5%3Y −58.2%5Y −82.8%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 421 companies (100 = best)

6-month momentum34

Revenue growth69

Net margin48

Value (low P/E)—

Size76

Industry medians: 6-month return −23.4%, revenue growth +6.4%, net margin −39.7%, P/E 15.4×.

Short interest

Details →

Shares short20.3M+22.8% vs prior

Days to cover3.1Settled Sep 30

% of float21.8%

Short vol. 10d38.7%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
RAREUltragenyx Pharmaceutical	$14.90	−0.13%	−40.8%	+28.1%	−43.0%	—	$1.47B
QUREuniQure	$20.97	−1.46%	+21.6%	+11.0%	−1387.8%	—	$1.45B	Compare
PCRXPacira BioSciences	$36.40	+0.25%	+55.4%	+6.2%	2.4%	99.2	$1.45B	Compare
STOKStoke Therapeutics	$23.26	+3.38%	−34.6%	−32.5%	−660.8%	—	$1.50B	Compare
ETONEton Pharmaceutcials	$52.88	−0.84%	+96.1%	+98.6%	30.8%	119.1	$1.51B	Compare
INVAInnoviva	$20.97	+1.11%	−12.3%	+19.3%	−69.8%	4.2	$1.51B	Compare
PAHCPhibro Animal Health	$37.93	+3.04%	−31.0%	+4.8%	5.5%	15.4	$1.54B	Compare
ANABAnaptysBio	$46.67	+2.37%	−31.3%	−8.0%	−206.9%	—	$1.40B	Compare
KLRAKailera Therapeutics	$10.74	−0.28%	—	—	—	—	$1.39B	Compare

News about Ultragenyx Pharmaceutical

All news →

Can RARE's Approved Product Portfolio Drive Its Next Growth Phase?Zacks Investment Research · 1d agoNeutral Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost CashZacks Investment Research · Oct 8, 2026▲ Positive Why Is Ultragenyx (RARE) Up 6.4% Since Last Earnings Report?Zacks Investment Research · Sep 3, 2026Neutral Amlogenyx to Present at the Wells Fargo 21ˢᵗ Annual Healthcare ConferenceGlobeNewswire Inc. · Sep 2, 2026Neutral Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc. · Jun 19, 2026Neutral

Quick answers

What does Ultragenyx Pharmaceutical do?: Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions.
What is RARE's market cap?: $1.47B, based on the Oct 14 close of $14.90.
Does Ultragenyx Pharmaceutical pay a dividend?: No regular cash dividend has been paid in the last year.
How much of RARE is sold short?: 20.3M shares, 21.8% of float, as of Sep 30, 2026.
What sector is RARE in?: Healthcare, in the Pharmaceuticals industry.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.

HQ: Novato, CA1,371 employeesListed Jan 31, 2014ultragenyx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology